Cargando…

Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis

New chemotherapeutic compounds are needed to combat multidrug-resistant Mycobacterium tuberculosis (Mtb), which remains a serious public-health challenge. Decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1 enzyme) has been characterized as an attractive therapeutic target to address this urgent dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Chao, Peng, Cuiting, Shi, Yaojie, You, Xinyu, Ran, Kai, Xiong, Lu, Ye, Ting-hong, Zhang, Lidan, Wang, Ningyu, Zhu, Yongxia, Liu, Kun, Zuo, Weiqiong, Yu, Luoting, Wei, Yuquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942819/ https://www.ncbi.nlm.nih.gov/pubmed/27405961 http://dx.doi.org/10.1038/srep29717

Ejemplares similares

Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
por: Zhu, Yongxia, et al.
Publicado: (2016)

Author Correction: Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
por: Zhu, Yongxia, et al.
Publicado: (2022)

Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
por: Song, Xuejiao, et al.
Publicado: (2016)

Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
por: Song, Xuejiao, et al.
Publicado: (2016)

A Novel Benzothiazole Derivative YLT322 Induces Apoptosis via the Mitochondrial Apoptosis Pathway In Vitro with Anti-Tumor Activity in Solid Malignancies
por: Xuejiao, Song, et al.
Publicado: (2013)

The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
por: Ye, Tinghong, et al.
Publicado: (2014)

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
por: Xia, Yong, et al.
Publicado: (2014)

A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity
por: Li, Xiao, et al.
Publicado: (2023)

YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect
por: Lei, Qian, et al.
Publicado: (2018)

A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo
por: Zeng, Jun, et al.
Publicado: (2022)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
por: Choi, Peter J., et al.
Publicado: (2020)

Developing Potential Candidates of Preclinical Preeclampsia
por: Founds, Sandra, et al.
Publicado: (2015)

Transplanted organoids empower human preclinical assessment of drug candidate for the clinic
por: Westerling-Bui, Amy D., et al.
Publicado: (2022)

Preclinical Testing of a Vaccine Candidate against Tularemia
por: Suresh, Ragavan Varadharajan, et al.
Publicado: (2015)

Core Outcome Measures in Preclinical Assessment of Candidate Analgesics
por: Negus, S. Stevens
Publicado: (2019)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
por: Wu, Xiao Yu, et al.
Publicado: (2015)

A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis
por: Peng, Cuiting, et al.
Publicado: (2019)

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
por: Rynearson, Kevin D., et al.
Publicado: (2021)

Preclinical evaluation of lime juice as a topical microbicide candidate
por: Fletcher, Patricia S, et al.
Publicado: (2008)

Identification of New Antiseizure Medication Candidates in Preclinical Animal Studies
por: Yang, Chih-Sheng, et al.
Publicado: (2023)

Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity
por: Aguiar, Anna C.C., et al.
Publicado: (2018)

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
por: Lunde, Christopher S., et al.
Publicado: (2019)

Metabolites of Xenorhabdus bacteria are potent candidates for mitigating amphibian chytridiomycosis
por: Ujszegi, János, et al.
Publicado: (2023)

Assessing and screening for T-cell epitopes from Mycobacterium tuberculosis RD2 proteins for the diagnosis of active tuberculosis
por: Chen, Jiazhen, et al.
Publicado: (2018)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.
por: Burger, A. M., et al.
Publicado: (1996)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
por: Oksvold, Morten P., et al.
Publicado: (2021)

Identification of Chaetocin as a Potent non-ROS-mediated Anticancer Drug Candidate for Gastric Cancer
por: Liao, Xinwen, et al.
Publicado: (2019)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
por: Wyllie, Susan, et al.
Publicado: (2019)

Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine
por: Gulati, Sunita, et al.
Publicado: (2019)

Diphenyl Difluoroketone: A Potent Chemotherapy Candidate for Human Hepatocellular Carcinoma
por: Liang, Yingjian, et al.
Publicado: (2011)

Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones
por: Chen, Yizhe, et al.
Publicado: (2021)

#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models
por: Lu, Wen-Jie, et al.
Publicado: (2018)

IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis
por: Zhu, Ningyu, et al.
Publicado: (2018)

Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent
por: Lv, Huiqing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q1c3lm0eal18ugc2rpam7r8f91